{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:05:02Z","timestamp":1772107502932,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.amjopharm.2011.07.004","type":"journal-article","created":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T06:21:47Z","timestamp":1313648507000},"page":"271-285","source":"Crossref","is-referenced-by-count":24,"title":["Management of Gout in the Older Adult"],"prefix":"10.1016","volume":"9","author":[{"given":"Michelle A.","family":"Fravel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2011.07.004_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib2","series-title":"Primer on the Rheumatic Diseases","first-page":"307","article-title":"Gout: epidemiology, pathology, and pathogenesis","author":"Terkeltaub","year":"2001"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18553\/jmcp.2008.14.2.164","article-title":"Disease-related and all-cause health care costs of elderly patients with gout","volume":"14","author":"Wu","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib4","series-title":"Primer on the Rheumatic Diseases","first-page":"313","article-title":"Gout: clinical and laboratory features","author":"Kimberly","year":"2001"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia: risks and consequences in the normative aging study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.080487","article-title":"Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?","volume":"36","author":"Wu","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib7","author":"Ernst"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib8","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib9","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006190","article-title":"Colchicine for acute gout","volume":"4","author":"Schlesinger","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/art.1780130207","article-title":"The early history of antirheumatic drugs","volume":"13","author":"Rodnan","year":"1970","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib13","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib14","first-page":"301","article-title":"Does colchicine work?","volume":"17","author":"Ahren","year":"1987","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib16","first-page":"341","article-title":"Drug Topics Red Book","year":"2010"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib17","series-title":"Colcrys (colchicine) [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib18","first-page":"498","article-title":"Gout in ambulatory care settings in the United States","volume":"35","author":"Krishnan","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib19","first-page":"915","article-title":"An evaluation of piroxicam, a new non-steroidal anti-inflammatory agent: a multicentre trial","volume":"59","author":"Tweddell","year":"1981","journal-title":"S Afr Med J"},{"issue":"Suppl 3A","key":"10.1016\/j.amjopharm.2011.07.004_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9343(86)90131-2","article-title":"Flurbiprofen in the treatment of acute gout: a comparison with indomethacin","volume":"80","author":"Lomen","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib21","first-page":"1422","article-title":"Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study","volume":"15","author":"Altman","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1185\/03007999109111513","article-title":"Effectiveness of etodolac (\u2018Lodine\u2019) compared with naproxen in patients with acute gout","volume":"12","author":"Maccagno","year":"1991","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0196-0644(95)70037-4","article-title":"Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis","volume":"26","author":"Shrestha","year":"1995","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib24","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/kel071","article-title":"Effectiveness of interventions for the treatment of acute and prevention of recurrent gout\u2014a systematic review","volume":"45","author":"Sutaria","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etorcoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib27","series-title":"Fundamentals of Geriatric Medicine: A Case-Based Approach","first-page":"39","article-title":"Geriatric pharmacology and drug prescribing for older adults","author":"Leipzig","year":"2007"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jama.264.4.471","article-title":"Nonsteroidal anti-inflammatory drug-associated azotemia in the very old","volume":"264","author":"Gurwitz","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib29","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.158.10.1108","article-title":"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics","volume":"158","author":"Heerdink","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/oxfordjournals.aje.a117469","article-title":"Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons","volume":"141","author":"Smalley","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archinte.152.6.1289","article-title":"The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease","volume":"152","author":"Bollini","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":"Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind randomized, controlled trial","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib33","first-page":"111","article-title":"Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis","volume":"20","author":"Alloway","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib34","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis","volume":"21","author":"Siegel","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005521.pub2","article-title":"Systemic corticosteroids for acute gout","volume":"2","author":"Janssens","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib36","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib37","first-page":"2285","article-title":"Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide","volume":"26","author":"Fernandez","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib38","first-page":"908","article-title":"A cost effectiveness analysis of urate lowering drugs in nontophaceous [ref]recurrent gouty arthritis","volume":"22","author":"Ferraz","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3949\/ccjm.69.8.594","article-title":"Asymptomatic hyperuricemia: to treat or not to treat","volume":"69","author":"Dincer","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib42","series-title":"Zyloprim (allopurniol) [package insert]","year":"2003"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib44","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.clinthera.2009.11.033","article-title":"Febuxostat: a selective xanthine-oxidase\/xanthine dehydrogenase inhibitor for the management of hyperuricemia in adults with gout","volume":"31","author":"Ernst","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib45","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor xanthine oxidase: a twenty-eight day, multicenter, phase II, randomized, double-blind, placebo controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 9","key":"10.1016\/j.amjopharm.2011.07.004_bib47","first-page":"S530","article-title":"Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase\/xanthine dehydrogenase inhibitor, for gout and hyperuricemia","volume":"48","author":"Kamatani","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"10.1016\/j.amjopharm.2011.07.004_bib48","first-page":"S337","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia","volume":"50","author":"Kamatani","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib49","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib50","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib51","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: s 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib52","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib53","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0091270008322035","article-title":"The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase","volume":"48","author":"Khosravan","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib54","first-page":"794","article-title":"Drug Topics Red Book","year":"2010"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0026-0495(88)90098-4","article-title":"Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (benzafibrate and fenofibrate) in a double-blind, placebo-controlled trial","volume":"37","author":"Bastow","year":"1988","journal-title":"Metabolism"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib56","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout","volume":"19","author":"Wurzner","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib57","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","article-title":"Prophylactic colchicine therapy of intercritical gout: a placebo-controlled study of probenecid-treated patients","volume":"17","author":"Paulus","year":"1974","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib60","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib61","first-page":"179","article-title":"Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients?","volume":"11","author":"De Angelis","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib62","first-page":"737","article-title":"A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function","volume":"10","author":"Malaguarnera","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib63","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib64","series-title":"Krystexxa (pegloticase) [package insert]","year":"2010"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib66","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2011.07.004_bib67","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594611001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594611001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:54:28Z","timestamp":1638320068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594611001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1543594611001206"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2011.07.004","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}